ABBOTT PARK, Ill., Aug. 30, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data from the Amulet™ LAA Occluder IDE trial, a multi-center, head-to-head study comparing the company ...

New Guidelines Issued for Management of Atrial Fibrillation The Amulet device is designed for complete immediate closure of the left atrial appendage using dual-seal technology. Using dual-seal ...

Abbott has received a new, broad approval from the FDA for its tiny heart plug implant to help cut down the risk of stroke among people with atrial fibrillation, the most common cardiac arrhythmia.

First and only steerable delivery system designed to help seal the left atrial appendage (LAA) in people with atrial fibrillation who are at an increased risk of stroke Now available in the U.S., ...

Abbott Laboratories (NYSE:ABT) is recalling the Amplatzer Steerable Delivery Sheath due to an increased risk for air bubbles (air emboli) to be introduced into patients who have procedures with this ...

BOSTON, MA—For patients with atrial fibrillation who are undergoing left atrial appendage occlusion (LAAO), the Amplatzer Amulet (Abbott) and the first-generation Watchman 2.5 (Boston Scientific) ...

SAN FRANCISCO -- Two mainstream devices for percutaneous left atrial appendage (LAA) closure continued to lead to similar clinical outcomes in the SWISS-APERO trial. Among patients randomized to the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. BOSTON — At 3 years, the Amplatzer Amulet device ...

Abbott is recalling the Amplatzer steerable delivery sheath, used to deliver the Amplatzer Amulet left atrial appendage occluder during cardiac catheterization, because of an increased risk of air ...

High-risk patients with atrial fibrillation may have better outcomes with left atrial appendage (LAA) closure with the Amplatzer Amulet device (Abbott) than with direct oral anticoagulant (DOAC) ...

Abbott Laboratories received FDA approval for its Amplatzer Amulet left atrial appendage occluder to treat people with atrial fibrillation who are at risk of ischemic stroke about a month earlier than ...

Abbott Laboratories ABT recently presented late-breaking data from the Amulet LAA Occluder IDE trial comparing the company's Amplatzer Amulet Left Atrial Appendage (LAA) Occluder with Boston ...